ArticleInternational journal of women's health2025
Efficacy and Safety of Shatavari (
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Unraveling the Mechanistic Insights ofNutrients · 2026Review
- Ayurvedic Medicinal Plants and Plant-Derived Extracellular Vesicles: Current Evidence and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2026Review
- SheVari4Food & nutrition research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Perimenopause is a natural phenomenon caused by hormonal changes, often accompanied by symptoms such as hot flashes and mood swings that can affect women's quality of life. Due to concerns about hormonal treatments, women often seek plant-based alternatives. Shatavari ( Patients and Methods: This prospective, randomized, double-blind, placebo-controlled study screened 120 women, and 80 were eligible participants and were randomly assigned to receive either Shatavari root extract (SHT; n = 40) or placebo (PL; n = 40). Seventy-three participants completed the study per protocol (SHT: n = 37; PL: n = 36). Symptom changes were assessed using scales such as the Menopause Rating Scale (MRS), Menopause-Specific Quality of Life (MENQOL) scale, Profile of Mood States (POMS) scale, and Perceived Stress Scale (PSS) at baseline, week 4, and week 8. Blood tests were also conducted to monitor hormone levels and safety markers. Results: The SHT group demonstrated a significant improvement in MRS (somato-vegetative, psychological, and urogenital domains) and PSS scores (p < 0.0001). Furthermore, it showed enhancements in fatigue (p = 0.019) at week 8, vigor (p = 0.021) at week 4, and stress reductions at week 4 (p = 0.010) and week 8 (p < 0.0001). Hot flashes improved significantly more (p = 0.002) with SHT group. Estradiol (p = 0.003), Follicle Stimulating Hormone (p = 0.028), and T3 (p = 0.021) levels increased with no adverse effects observed on liver or kidney function. Conclusion: Shatavari root extract may be an effective and safe natural intervention for the treatment of perimenopausal symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.